[
  {
    "ts": "2026-02-13T02:07:28+00:00",
    "headline": "Vertex Pharmaceuticals Q4 Earnings Call Highlights",
    "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple late-stage pipeline milestones while reviewing fourth-quarter and full-year 2025 results on its earnings call. Executives highlighted continued strength in cystic fibrosis (CF),",
    "url": "https://www.marketbeat.com/instant-alerts/vertex-pharmaceuticals-q4-earnings-call-highlights-2026-02-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "a2440f9d-16b1-3da8-9c59-3446d548e6a3",
      "content": {
        "id": "a2440f9d-16b1-3da8-9c59-3446d548e6a3",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple late-stage pipeline milestones while reviewing fourth-quarter and full-year 2025 results on its earnings call. Executives highlighted continued strength in cystic fibrosis (CF),",
        "pubDate": "2026-02-13T02:07:28Z",
        "displayTime": "2026-02-13T02:07:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/2b24107d7189be99d174df28e69c0745",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Vertex Pharmaceuticals logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_R3e5J4xXhGqswXyjpPPAA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/2b24107d7189be99d174df28e69c0745.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B1sm63HzQpEVAehsaVnbbQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/2b24107d7189be99d174df28e69c0745.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/vertex-pharmaceuticals-q4-earnings-call-highlights-2026-02-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-q4-earnings-call-020728764.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "RPRX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T05:05:06+00:00",
    "headline": "Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
    "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 10% revenue increase in Q4 2025, driven by successful product launches and strategic pipeline advancements.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q4-050506194.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "578cedd8-fe88-3d41-a06a-946f5e7a0ad6",
      "content": {
        "id": "578cedd8-fe88-3d41-a06a-946f5e7a0ad6",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Inc (VRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
        "description": "",
        "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 10% revenue increase in Q4 2025, driven by successful product launches and strategic pipeline advancements.",
        "pubDate": "2026-02-13T05:05:06Z",
        "displayTime": "2026-02-13T05:05:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q4-050506194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q4-050506194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T09:19:47+00:00",
    "headline": "Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential",
    "summary": "Vertex Pharmaceuticals received FDA orphan drug designation for povetacicept in myasthenia gravis. The company announced an alliance with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases. Both updates relate to Vertex expanding its rare disease and autoimmune portfolio beyond cystic fibrosis. Vertex Pharmaceuticals, NasdaqGS:VRTX, is drawing fresh attention as it adds new rare disease and autoimmune assets alongside its established cystic...",
    "url": "https://finance.yahoo.com/news/vertex-expands-autoimmune-pipeline-investors-091947626.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "48ffa8ba-0ed5-3421-bc57-40751c0f4df4",
      "content": {
        "id": "48ffa8ba-0ed5-3421-bc57-40751c0f4df4",
        "contentType": "STORY",
        "title": "Vertex Expands Autoimmune Pipeline As Investors Weigh Valuation And Growth Potential",
        "description": "",
        "summary": "Vertex Pharmaceuticals received FDA orphan drug designation for povetacicept in myasthenia gravis. The company announced an alliance with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases. Both updates relate to Vertex expanding its rare disease and autoimmune portfolio beyond cystic fibrosis. Vertex Pharmaceuticals, NasdaqGS:VRTX, is drawing fresh attention as it adds new rare disease and autoimmune assets alongside its established cystic...",
        "pubDate": "2026-02-13T09:19:47Z",
        "displayTime": "2026-02-13T09:19:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-expands-autoimmune-pipeline-investors-091947626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-expands-autoimmune-pipeline-investors-091947626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "WXIBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:54:53+00:00",
    "headline": "Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow […]",
    "url": "https://finance.yahoo.com/news/vertex-pharma-vrtx-renal-pipeline-145453047.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "809e5a1a-5793-31d5-a705-58c877374d30",
      "content": {
        "id": "809e5a1a-5793-31d5-a705-58c877374d30",
        "contentType": "STORY",
        "title": "Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays",
        "description": "",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $606 price target, voicing confidence about Vertex’s renal franchise, implying that it might achieve significant market attention in 2026 and perhaps follow […]",
        "pubDate": "2026-02-13T14:54:53Z",
        "displayTime": "2026-02-13T14:54:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ebfc00a4e36a86ae93bae37394969574",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OrUjEhTQ558OAB4v1CuhoA--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ebfc00a4e36a86ae93bae37394969574.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0loC6Itwxz._frgmtnABlQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ebfc00a4e36a86ae93bae37394969574.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharma-vrtx-renal-pipeline-145453047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharma-vrtx-renal-pipeline-145453047.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "BCS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:04:00+00:00",
    "headline": "CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates",
    "summary": "CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.",
    "url": "https://finance.yahoo.com/news/crsp-posts-wider-expected-loss-150400732.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "79a481e0-c74c-3b1b-a9d8-22b3742988cd",
      "content": {
        "id": "79a481e0-c74c-3b1b-a9d8-22b3742988cd",
        "contentType": "STORY",
        "title": "CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates",
        "description": "",
        "summary": "CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.",
        "pubDate": "2026-02-13T15:04:00Z",
        "displayTime": "2026-02-13T15:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crsp-posts-wider-expected-loss-150400732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crsp-posts-wider-expected-loss-150400732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T17:41:10+00:00",
    "headline": "Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says",
    "summary": "Vertex Pharmaceuticals' (VRTX) Q4 was \"somewhat anticlimactic\" from a pipeline perspective, but soli",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-q4-apos-anticlimactic-174110514.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "368cfcfe-3ed2-3a58-85d4-274cd82c447b",
      "content": {
        "id": "368cfcfe-3ed2-3a58-85d4-274cd82c447b",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says",
        "description": "",
        "summary": "Vertex Pharmaceuticals' (VRTX) Q4 was \"somewhat anticlimactic\" from a pipeline perspective, but soli",
        "pubDate": "2026-02-13T17:41:10Z",
        "displayTime": "2026-02-13T17:41:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-q4-apos-anticlimactic-174110514.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-q4-apos-anticlimactic-174110514.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T16:53:00+00:00",
    "headline": "VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales",
    "summary": "Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.",
    "url": "https://finance.yahoo.com/news/vrtxs-q4-earnings-miss-mark-165300065.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "dc5768b9-bd0c-3c34-b396-964b124af6e0",
      "content": {
        "id": "dc5768b9-bd0c-3c34-b396-964b124af6e0",
        "contentType": "STORY",
        "title": "VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales",
        "description": "",
        "summary": "Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.",
        "pubDate": "2026-02-13T16:53:00Z",
        "displayTime": "2026-02-13T16:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/clkf5pUY76l.nElrYS4s6w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Fd4LKz3FaED4STL9jWy9kw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vrtxs-q4-earnings-miss-mark-165300065.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vrtxs-q4-earnings-miss-mark-165300065.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T05:32:06+00:00",
    "headline": "VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $5.03 per share was 2.3% below analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/vrtx-q4-deep-dive-diversification-053206455.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7d0e7baa-18a6-325c-852e-e754245403f4",
      "content": {
        "id": "7d0e7baa-18a6-325c-852e-e754245403f4",
        "contentType": "STORY",
        "title": "VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase",
        "description": "",
        "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $5.03 per share was 2.3% below analysts’ consensus estimates.",
        "pubDate": "2026-02-13T05:32:06Z",
        "displayTime": "2026-02-13T05:32:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VRTX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6Y31wu10RiElUns.3mORA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qe_uhCRKlCGgByoENi3GZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vrtx-q4-deep-dive-diversification-053206455.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vrtx-q4-deep-dive-diversification-053206455.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T19:22:51+00:00",
    "headline": "Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)",
    "summary": "A sales partner offered a ray of hope that this company couldn't for itself.",
    "url": "https://www.fool.com/investing/2026/02/13/why-crispr-therapeutics-stock-is-up-today-despite/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "936462bb-9e63-3f26-8c43-218d3773f619",
      "content": {
        "id": "936462bb-9e63-3f26-8c43-218d3773f619",
        "contentType": "STORY",
        "title": "Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)",
        "description": "",
        "summary": "A sales partner offered a ray of hope that this company couldn't for itself.",
        "pubDate": "2026-02-13T19:22:51Z",
        "displayTime": "2026-02-13T19:22:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/de50bc960872adc7c230b0183fd77d4a",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "An investor sits in front of a desk while looking at a laptop.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hz9_OLTuBQqd8E0ygU9xlQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/de50bc960872adc7c230b0183fd77d4a.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x9DVZ1.nrzBX8raYGLuxjg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/de50bc960872adc7c230b0183fd77d4a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/13/why-crispr-therapeutics-stock-is-up-today-despite/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-crispr-therapeutics-stock-today-192251379.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T13:00:21+00:00",
    "headline": "Vertex’s CRISPR therapy rebounds in latest earnings",
    "summary": "Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.",
    "url": "https://www.biopharmadive.com/news/vertex-earnings-casgevy-q4-2025/812243/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "e8dc5135-812b-3f6c-86f7-5aabedc510ba",
      "content": {
        "id": "e8dc5135-812b-3f6c-86f7-5aabedc510ba",
        "contentType": "STORY",
        "title": "Vertex’s CRISPR therapy rebounds in latest earnings",
        "description": "",
        "summary": "Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.",
        "pubDate": "2026-02-13T13:00:21Z",
        "displayTime": "2026-02-13T13:00:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/vertex-earnings-casgevy-q4-2025/812243/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-crispr-therapy-rebounds-latest-130021555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "CRSP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T13:30:00+00:00",
    "headline": "Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary",
    "summary": "Moby summary of Vertex Pharmaceuticals Incorporated's Q4 2025 earnings call",
    "url": "https://app.moby.co/home/research/tools/earningsCalendar/earnings-vertex-pharmaceuticals-incorporated-q4-2025-earnings-call-summary?utm_source=yahoo_finance&utm_medium=rss",
    "source": "Moby",
    "provider": "yfinance",
    "raw": {
      "id": "54ea9db1-a707-327f-9090-fb424be4d0c5",
      "content": {
        "id": "54ea9db1-a707-327f-9090-fb424be4d0c5",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary",
        "description": "",
        "summary": "Moby summary of Vertex Pharmaceuticals Incorporated's Q4 2025 earnings call",
        "pubDate": "2026-02-13T13:30:00Z",
        "displayTime": "2026-02-13T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/moby_896/e9403906139bce5e373cb0cf8b94cdf3",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RfddIiOfSS_nO1WQm0uXlw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/moby_896/e9403906139bce5e373cb0cf8b94cdf3.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vo2bkW1dy_VUWV6BEjWG_A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/moby_896/e9403906139bce5e373cb0cf8b94cdf3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Moby",
          "url": "https://moby.co/"
        },
        "canonicalUrl": {
          "url": "https://app.moby.co/home/research/tools/earningsCalendar/earnings-vertex-pharmaceuticals-incorporated-q4-2025-earnings-call-summary?utm_source=yahoo_finance&utm_medium=rss",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-q4-2025-133000335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T20:51:00+00:00",
    "headline": "Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. Wh",
    "url": "https://finance.yahoo.com/news/moderna-vertex-pharmaceuticals-integra-lifesciences-205100159.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "dec8c97c-a955-340f-889f-88e6434d71e8",
      "content": {
        "id": "dec8c97c-a955-340f-889f-88e6434d71e8",
        "contentType": "STORY",
        "title": "Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know",
        "description": "",
        "summary": "A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. Wh",
        "pubDate": "2026-02-13T20:51:00Z",
        "displayTime": "2026-02-13T20:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "MRNA Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xFZGGzZnWM6N6sCUARtq9w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiku5oDkVhvbobAoAonIcg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/7ed68d581c33e574792b9fa0fe3f670c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-vertex-pharmaceuticals-integra-lifesciences-205100159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-vertex-pharmaceuticals-integra-lifesciences-205100159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "MOH"
            },
            {
              "symbol": "IART"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "BAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]